Supernus Pharmaceuticals Inc (SUPN)

Cash ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash and cash equivalents	US$ in thousands	75,054	94,985	24,706	58,442	93,120	111,492	173,428	115,715	203,434	215,281	223,771	255,642	288,640	204,293	210,975	225,767	181,381	116,889	87,344	122,778
Short-term investments	US$ in thousands	179,820	105,204	126,950	170,126	368,214	280,297	187,359	196,485	136,246	228,571	186,070	135,459	133,893	147,657	163,839	175,104	165,692	179,808	171,222	170,165
Total current liabilities	US$ in thousands	290,196	287,534	252,590	731,545	687,958	725,987	735,536	284,558	315,379	234,711	283,447	240,812	245,108	299,606	269,276	168,335	160,587	149,717	143,971	151,706
Cash ratio		0.88	0.70	0.60	0.31	0.67	0.54	0.49	1.10	1.08	1.89	1.45	1.62	1.72	1.17	1.39	2.38	2.16	1.98	1.80	1.93

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($75,054K + $179,820K) ÷ $290,196K
= 0.88

The cash ratio for Supernus Pharmaceuticals Inc has shown fluctuations over the past eight quarters. The ratio peaked in Q1 2022 at 1.18, indicating that the company had $1.18 in cash and cash equivalents for every $1 of current liabilities. However, it steadily declined in subsequent quarters, reaching its lowest point in Q1 2023 at 0.33, suggesting a decrease in the company's ability to cover its short-term obligations with cash on hand.

Although there was a slight improvement in the cash ratio in Q4 2023 to 0.94, it remained below the levels seen in previous periods. This indicates that while Supernus Pharmaceuticals Inc has been able to increase its cash reserves compared to the previous quarter, the company may still have limited liquidity to meet its current liabilities.

Overall, the fluctuating trend of the cash ratio for Supernus Pharmaceuticals Inc suggests that the company should continue to monitor its liquidity position closely and ensure it maintains an appropriate level of cash reserves to meet its short-term obligations effectively.